U.S. flag

An official website of the United States government

Here’s how you know
Here’s how you know

**Official websites use .gov**
A **.gov** website belongs to an official government organization in the United States.

**Secure .gov websites use HTTPS**
A **lock** ( A locked padlock) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Search Query:
			MAIN MENU

																				
              Health Topics
								All Health Topics A-Z
					
													
		

		Asthma


				

															Heart-Healthy Living


				

															High Blood Pressure


				

															Sickle Cell Disease


				

															Sleep Apnea


				

															Information & Resources on COVID-19
																				
              Health Education
								Education Programs and Initiatives
					
													
		

		The Heart Truth®


				

															Learn More Breathe Better®


				

															Blood Diseases and Disorders Education Program


				

															Publications and Resources
																				
              The Science
								Research Focus Areas
					
													
		

		Blood Disorders and Blood Safety


				

															Sleep Science and Sleep Disorders


				

															Lung Diseases


				

															Health Disparities and Inequities


				

															Heart and Vascular Diseases


				

															Precision Medicine Activities


				

															Obesity, Nutrition, and Physical Activity


				

															Population and Epidemiology Studies


				

															Women’s Health


				

															Research Topics


				

															Clinical Trials


				

															All Science A-Z
																				
              Grants and Training
								Grants and Training Home


				

															Policies and Guidelines


				

															Funding Opportunities and Contacts


				

															Training and Career Development
																				
              News and Events
								News and Events Home
					
													
		

		Email Alerts


				

															All News
					
													
		

		NHLBI News


				

															NHLBI in the Press


				

															Research Features


				

															All Events
					
													
		

		Past Events


				

															Upcoming Events
																				
              About NHLBI
								About NHLBI Home
					
													
		

		Mission and Strategic Vision


				

															Leadership


				

															Divisions, Offices and Centers


				

															Advisory Committees


				

															Budget and Legislative Information


				

															Jobs and Working at the NHLBI


				

															Contact and FAQs


				

															NIH Sleep Research Plan
						
						HOME
		Search Text: Home/News and Events/< Back ToAll News/Lipoprotein(a): What to know about elevated levels

A lipoprotein(a) blood test is shown.
                                                        RESEARCH FEATURE
                                
                                Lipoprotein(a): What to know about elevated levels
                                
                                                                 January 17, 2024
                                    If you’ve listened to the radio or opened a webpage in the past year, you may have seen or heard ads promoting lipoprotein(a), or Lp(a), testing to help people identify risks for heart disease.But, what *is* Lp(a)? Most importantly: should you get your levels tested?Lp(a) is a type of lipid, or fat, in the body that contains and is similar in structure to low-density lipoprotein (LDL) cholesterol, often thought of as “bad cholesterol.” Like LDL cholesterol, Lp(a) deposits cholesterol in the arteries and can show up in plaque. It’s also found in cells that line small blood vessels and in tissues where regeneration and healing occur.“There is a lot of intrigue about it,” said Sotirios Tsimikas, M.D., an Lp(a) researcher and professor of medicine at the University of California San Diego. “Is it just an error of evolution that became very common? Does it have a physiological function? We don’t know.”The lipoprotein’s composition, which includes other lipoproteins, has also made it a prime research target. “Lp(a) is more complex than LDL,” said Lijuan Liu, Ph.D., a program officer who specializes in lipid metabolism and atherosclerosis in the Division of Cardiovascular Sciences at NHLBI.“It seems to have all the same bad features as LDL,” added Alan T. Remaley, M.D., Ph.D., a senior investigator in NHLBI’s Lipoprotein Metabolism Laboratory, “but some extra harmful features that we don’t fully understand.” For example, he explained that Lp(a) acts as a molecule that supports clotting, and this, among other features, appears to make it even worse than LDL as a risk marker for cardiovascular disease.Here's more of what researchers have found about Lp(a) and what studies may soon reveal:Elevated Lp(a) levels are a cardiovascular disease risk factorFor decades increased Lp(a) levels have been linked to a higher risk for cardiovascular disease. This now includes heart attack, stroke, and a range of conditions like irregular heart rhythms, heart valve disease, and limited lower-body circulation. The connections crystalized in the late 1990s when researchers, like those in Tsimikas’ lab, started seeing more patients with elevated Lp(a) levels who needed coronary revascularizations, a procedure to restore blood flow to and around the heart.Around the same time, the researchers were learning about how Lp(a) was linked to inflammation, which tracked with what they saw at the hospital. Genetic studies soon found that some people had different expressions of the *LPA* gene, which could increase their risk for having elevated Lp(a) levels.Today, about 20-30% of people worldwide are estimated to have elevated levels of Lp(a), which are generally thought to start between 30-50 mg/dL.Tsimikas explained that Lp(a) is likely the leading inherited risk for cardiovascular disease. “It’s more heritable than hypertension, diabetes, and obesity,” he said. However, “Even if the level is elevated, it doesn’t mean you are going to have an event. It just puts you at a higher risk.”Preventive screenings are increasingly used to gauge risksReassuringly, most people — about 70-75% — would have low Lp(a) levels if they were screened today, said Tsimikas. Preventive screenings are designed to identify the smaller proportion of people with elevated levels.In the U.S., Lp(a) testing is recommended for people younger than age 65 who have had a heart attack, those with a family history of premature heart disease, and those with elevated LDL cholesterol who haven’t responded to statins, cholesterol-lowering drugs that can lower LDL levels by about 30%.Since elevated Lp(a) levels are largely due to genetic risks and don’t fluctuate much in response to modifiable risks, such as exercise, a one-time screening would be sufficient for most people, the experts noted. In Europe and Canada, Lp(a) screenings are recommended for everyone.Large clinical trials are testing Lp(a)-lowering therapiesCurrently, if a person has elevated Lp(a) levels, they would likely work with their physician to create a plan to take steps to support heart-healthy living and minimize any risks, such as having high blood pressure or high cholesterol. Some patients may also consider taking LDL cholesterol-lowering treatments, such as statins or PCSK9 inhibitors. In some cases, PCSK9 inhibitors have been shown to lower Lp(a) levels by about 20-30%. Lipoprotein apheresis, which removes excess Lp(a) and LDL cholesterol from the body, is another option, but for people with higher risks.Researchers are also studying targeted approaches to lower Lp(a) and approaches to further support patients. Tsimikas is studying the effect that aspirin may have in reducing inflammation for people with elevated Lp(a) levels. Additionally, other research, conducted through a large phase 3 trial is testing if a medication can****lower Lp(a) levels. Another trial is studying how to block its production. Results from both studies will be available in about two to three years.A secondary focus of ongoing Lp(a) research is to identify if and when benefits occur at different points of intervention. Participants in the phase 3 studies have Lp(a) levels between 70-80 mg/dL. Future studies may find lowering Lp(a) to levels below 50 mg/dL or 20-30 mg/dL has benefits, but it’s too early to tell, said Tsimikas. “We’ll have to let the science drive us to decide at what Lp(a) level we should start thinking about treating Lp(a) as a risk factor,” he explained.“We’re hopeful,” Tsimikas said about the research. This is why he often tells parents he meets who have a young child with elevated Lp(a) levels to stay optimistic. “I tell them that by the time your 7-year-old has to worry about this, we’ll have a way to treat it.”ResourcesTo learn more about lipids and heart health, visit https://www.nhlbi.nih.gov/health/blood-cholesterol/diagnosis.To learn more about Lp(a) research, visit https://www.nhlbi.nih.gov/events/2017/future-research-directions-lipoproteina-and-cardiovascular-disease.
                                                                                        CONTACT
                                        nhlbi_news@nhlbi.nih.gov
        301-496-5449
        Ask for press officer on duty
                                                                                                                                    Contact
            nhlbi_news@nhlbi.nih.gov
        301-496-5449
        Ask for press officer on duty
                                                Related Health Topics
                                        Atherosclerosis
              Coronary Heart Disease
              Blood Cholesterol
              What is Blood Cholesterol?
                                                                                                                                                            Related News & Features
                                        An updated test measures how well "good cholesterol" works
              Triglycerides: a new frontier in detecting and treating disease
              Calculating risks for heart disease Back To Top Link
  

        

        Back to top
  Web Policies & Notices
  

        

              Accessibility
                      No FEAR Act Data
                      Privacy Policy
                      Freedom of Information Act (FOIA)
                      HHS Vulnerability Disclosure
    
          Related Government Websites
  

        

              Health and Human Services
                      National Institutes of Health
                      Office of the Inspector General
                      USA.gov
    
          Stay Connected
    
      
            chat bubblesLive ChatLive Chat with us, Monday through Friday, 8:30 a.m. to 5:00 p.m. EST.envelopeGet Email AlertsReceive automatic alerts about NHLBI related news and highlights from across the Institute.
  Footer Bottom
  

        



Contact Us
                            Site Index
                            Jobs